ウィフガート（エフガルチギモド）の市場規模、シェア、動向分析レポート：適応症別、投与経路別、地域別、セグメント予測、2025年～2030年

ウィフガート（エフガルチギモド）市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のウィフガート（エフガルチギモド）市場規模は2030年までに55億米ドルに達すると予測され、2025年から2030年までのCAGRは13.6%で成長すると予測されています。

argenx SE社が開発したファーストインクラスの新生児Fc受容体（FcRn）拮抗薬であるウィフガート（efgartigimod）の市場は、複数の自己免疫適応症で治療領域が拡大するにつれて急速に発展しています。当初、重症筋無力症（gMG）の適応で承認されたウィフガートは、その後、原発性免疫性血小板減少症（ITP）および慢性炎症性脱髄性多発神経炎（CIDP）の治療薬として承認され、さらにFcRnに関連する免疫疾患の治療薬として開発が進められています。

ウィフガートの臨床的価値は、FcRnリサイクル経路を阻害することにより病原性IgG自己抗体を減少させるというユニークな作用機序にあります。この標的アプローチは、免疫系を広範囲に抑制することなく選択的な免疫調節を可能にし、良好な安全性プロファイルを提供します。本治療は、gMGやCIDPのような慢性的な抗体依存性疾患において確固たる有効性を示しており、他の自己免疫疾患においても本治療の使用を支持するエビデンスが増加しています。

特にgMGのような確立された適応症では、成人患者が最大の治療対象集団であるが、特に慢性自己免疫性神経障害や血液疾患では、小児への治療の可能性が高まっています。若年患者への早期介入は、疾患の進行を抑制し、広範な免疫抑制剤への依存を減らすことにより、長期的な利益をもたらす可能性があります。

専門薬局はウィフガートの流通モデルの最前線にあり、特に輸液製剤や皮下注製剤のため、的確な調整と患者サポートが必要です。病院薬局は、特に新たに診断された患者や重篤な患者にとって、導入剤や複雑な症例を管理する上で重要なパートナーであり続けています。専門的な販売チャネルは、個別化ケアプログラム、輸液スケジューリング、遠隔患者支援を通じて、ますますアクセスとアドヒアランスを強化しています。

2025年4月、FDAはgMGおよびCIDP患者の自己投与用にヒフデュラ配合皮下注のプレフィルドシリンジ製剤を承認しました。これにより、30秒未満での皮下投与が可能となり、治療の柔軟性とアドヒアランスが大幅に向上します。

また、2025年4月、EMAの欧州医薬品評価委員会（CHMP）は、欧州におけるCIDP治療薬としてVYVGART皮下注の承認を推奨する肯定的見解を発表し、同地域における30年以上ぶりのCIDP治療薬標的療法の承認に向けた準備が整いました。

2024年11月、ADHERE試験の良好な結果を受け、ヒフデュラ配合皮下注は中国においてCIDP治療薬として承認されました。これにより、アルジェンクスの世界の足跡はさらに拡大し、神経筋市場での地位は確固たるものとなりました。

世界的に需要が拡大する中、製品の安定供給はアルジェンクスの戦略的優先事項であり続けています。サプライチェーンの拡張性と患者中心のデジタルプラットフォームへの投資は、治療の継続性を強化し、医療提供者と患者の双方に力を与えています。これらのツールは、シームレスなケア移行とプロアクティブな疾患モニタリングが転帰に大きな影響を与える、長期にわたる再発性の自己免疫疾患の管理において特に重要です。

ウィフガートの成功は、特定の疾患経路を調節し、持続的な標的効果をもたらす精密免疫療法へのパラダイムシフトを強調するものです。自己免疫疾患に対する認識と診断能力が向上し続ける中、ウィフガートはFcRn阻害薬クラスの主要な選択肢であり続け、より良い転帰を促し、様々な衰弱性免疫介在性疾患における標準治療を再構築する準備が整っています。

ウィフガート（エフガルチギモド）市場レポート・ハイライト

• 適応症別では、重症筋無力症（gMG）が2024年のウィフガート（エフガルチギモド）市場において引き続き主要な適応症であり、抗体陽性患者の高い有病率とFcRn阻害による薬剤の標的作用機序により、最大のシェアを占めています。強力な臨床成績、良好な安全性プロファイル、治療ガイドラインの更新により、主要市場での採用が加速しています。
• 投与経路別では、点滴静注療法が2024年の投与経路別セグメントを支配しています。しかし、皮下投与製剤、特に最近承認されたプレフィルドシリンジへの移行が急速に進んでおり、自己投与が可能で患者の利便性が高まっています。
• 北米は、自己免疫疾患の高い診断率および治療率、有利な償還政策、強固な専門薬局インフラに支えられて、2024年のウィフガート市場を牽引しました。同地域はまた、臨床試験の活発化と革新的な免疫療法の早期採用からも利益を得ています。
• アルジェンクスSEは、強固な研究開発パイプライン、国際的な承認の拡大、中国のZai Labのような地域プレイヤーとの戦略的パートナーシップを活用し、引き続きウィフガート（エフガルチギモド）市場を世界にリードしました。同社は、サプライチェーンの回復力、患者支援プログラム、プラットフォームベースの開発に重点を置き、複数の適応症と地域にわたる長期的な成長を支えています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ウィフガート（エフガルチギモド）市場の変数、動向、および範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
• パイプライン分析
• 特許満了分析
• 価格分析

第4章 ウィフガート（エフガルチギモド）市場：適応症のビジネス分析

• 適応症市場シェア、2024年および2030年
• 適応症セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• 慢性炎症性脱髄性多発神経炎（CIDP）
• 全身性重症筋無力症（gMG）
• その他

第5章 ウィフガート（エフガルティギモド）市場：投与経路のビジネス分析

• 投与経路市場シェア、2024年および2030年
• 投与経路セグメントダッシュボード
• 市場規模、予測、動向分析（投与経路別、2018～2030年）
• 静脈内（IV）注入
• 皮下注射
• プレフィルドシリンジ

第6章 ウィフガート（エフガルティギモド）市場：地域の推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2018年から2030年まで：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Argenx SE

第8章 結論

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global Vyvgart (Efgartigimod) market, by region, 2018 - 2030 (USD Million)
• Table 4. Global Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 5. Global Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 6. North America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
• Table 7. North America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 8. North America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 9. U.S. Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 10. U.S. Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 11. Canada Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 12. Canada Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 13. Mexico Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 14. Mexico Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 15. Europe Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
• Table 16. Europe Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 17. Europe Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 18. UK Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 19. UK Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 20. Germany Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 21. Germany Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 22. France Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 23. France Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 24. Italy Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 25. Italy Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 26. Spain Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 27. Spain Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 28. Norway Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 29. Norway Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 30. Denmark Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 31. Denmark Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 32. Sweden Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 33. Sweden Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 34. Asia Pacific Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
• Table 35. Asia Pacific Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 36. Asia Pacific Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 37. Japan Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 38. Japan Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 39. China Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 40. China Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 41. India Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 42. India Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 43. Australia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 44. Australia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 45. South Korea Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 46. South Korea Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 47. Thailand Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 48. Thailand Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 49. Latin America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
• Table 50. Latin America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 51. Latin America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 52. Brazil Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 53. Brazil Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 54. Argentina Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 55. Argentina Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 56. Middle East & Africa Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
• Table 57. Middle East & Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 58. Middle East & Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 59. South Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 60. South Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 61. Saudi Arabia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 62. Saudi Arabia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 63. UAE Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 64. UAE Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
• Table 65. Kuwait Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
• Table 66. Kuwait Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Vyvgart (Efgartigimod) market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Indication and route of administration outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Vyvgart (Efgartigimod) market dynamics
• Fig. 12 Vyvgart (Efgartigimod) market: Porter's five forces analysis
• Fig. 13 Vyvgart (Efgartigimod) market: PESTLE analysis
• Fig. 14 Indication market, 2018 - 2030 (USD Million)
• Fig. 15 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, 2018 - 2030 (USD Million)
• Fig. 16 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
• Fig. 17 Others market, 2018 - 2030 (USD Million)
• Fig. 18 Route of Administration market, 2018 - 2030 (USD Million)
• Fig. 19 Intravenous (IV) Infusion market, 2018 - 2030 (USD Million)
• Fig. 20 Subcutaneous (SC) Injection market, 2018 - 2030 (USD Million)
• Fig. 21 Prefilled Syringe market, 2018 - 2030 (USD Million)
• Fig. 22 Vyvgart (Efgartigimod) market revenue, by region
• Fig. 23 Regional marketplace: Key takeaways
• Fig. 24 North America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 25 U.S. country dynamics
• Fig. 26 U.S. Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 27 Canada country dynamics
• Fig. 28 Canada Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 29 Mexico country dynamics
• Fig. 30 Mexico Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 31 Europe Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 32 UK country dynamics
• Fig. 33 UK Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 34 Germany country dynamics
• Fig. 35 Germany Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 36 France country dynamics
• Fig. 37 France Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 38 Italy country dynamics
• Fig. 39 Italy Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 40 Spain country dynamics
• Fig. 41 Spain Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 42 Norway country dynamics
• Fig. 43 Norway Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 44 Sweden country dynamics
• Fig. 45 Sweden Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 46 Denmark country dynamics
• Fig. 47 Denmark Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 48 Asia Pacific Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 49 Japan country dynamics
• Fig. 50 Japan Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 51 China country dynamics
• Fig. 52 China Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 53 India country dynamics
• Fig. 54 India Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 55 Australia country dynamics
• Fig. 56 Australia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 57 South Korea country dynamics
• Fig. 58 South Korea Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 59 Thailand country dynamics
• Fig. 60 Thailand Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 61 Latin America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 62 Brazil country dynamics
• Fig. 63 Brazil Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 64 Argentina country dynamics
• Fig. 65 Argentina Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 66 MEA Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 67 South Africa country dynamics
• Fig. 68 South Africa Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 69 Saudi Arabia country dynamics
• Fig. 70 Saudi Arabia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 71 UAE country dynamics
• Fig. 72 UAE Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 73 Kuwait country dynamics
• Fig. 74 Kuwait Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
• Fig. 75 Company categorization
• Fig. 76 Company market position analysis
• Fig. 77 Strategic framework

Vyvgart (Efgartigimod) Market Growth & Trends:

The global Vyvgart (Efgartigimod) market size is anticipated to reach USD 5.50 billion by 2030 and is projected to grow at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Vyvgart (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) antagonist developed by argenx SE, is rapidly evolving as its therapeutic footprint expands across multiple autoimmune indications. Initially approved for generalized myasthenia gravis (gMG), Vyvgart has since entered the treatment landscapes for Primary Immune Thrombocytopenia (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with ongoing exploration into additional FcRn-related immune disorders.

Vyvgart's clinical value lies in its unique mechanism of action that reduces pathogenic IgG autoantibodies by inhibiting the FcRn recycling pathway. This targeted approach allows for selective immunomodulation without broadly suppressing the immune system, offering a favorable safety profile. The treatment has demonstrated robust efficacy in chronic, antibody-driven conditions like gMG and CIDP, with growing evidence supporting its use across other autoimmune indications.

While adult patients represent the largest treated population, especially in well-established indications such as gMG, the therapeutic potential for pediatric use is gaining momentum, particularly in chronic autoimmune neuropathies and hematologic disorders. Early intervention in younger patients could offer long-term benefits by curbing disease progression and reducing reliance on broad-spectrum immunosuppressants.

Specialty pharmacies are at the forefront of Vyvgart's distribution model, particularly due to the drug's infusion-based and subcutaneous formulations, which require precise coordination and patient support. Hospital pharmacies continue to be key partners in managing induction and complex cases, especially for newly diagnosed or severely affected patients. Increasingly, specialty distribution channels are enhancing access and adherence through personalized care programs, infusion scheduling, and remote patient engagement.

In April 2025, the FDA approved a prefilled syringe formulation of VYVGART Hytrulo for self-administration in patients with gMG and CIDP. This enables subcutaneous delivery in under 30 seconds, significantly improving treatment flexibility and adherence.

Also in April 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of VYVGART subcutaneous injection for CIDP in Europe, setting the stage for the first targeted CIDP therapy approval in the region in over three decades.

In November 2024, VYVGART Hytrulo received regulatory approval in China for treating CIDP, following strong results from the ADHERE trial. This further expanded its global footprint and solidified Argenx's position in neuromuscular markets.

As demand grows globally, ensuring consistent product availability remains a strategic priority for argenx. Investments in supply chain scalability and patient-centered digital platforms are reinforcing treatment continuity and empowering both providers and patients. These tools are especially critical in managing long-term, relapsing autoimmune conditions, where seamless care transitions and proactive disease monitoring can significantly impact outcomes.

The success of Vyvgart underscores a broader paradigm shift toward precision immunotherapies that modulate specific disease pathways with durable, targeted effects. As awareness and diagnostic capabilities for autoimmune diseases continue to improve, Vyvgart is poised to remain a leading option in the FcRn inhibition class, driving better outcomes and reshaping the standard of care across a range of debilitating immune-mediated disorders.

Vyvgart (Efgartigimod) Market Report Highlights:

• Based on indication, Generalized Myasthenia Gravis (gMG) remained the leading indication in the Vyvgart (Efgartigimod) market in 2024, accounting for the largest share due to the high prevalence of antibody-positive patients and the drug's targeted mechanism of action through FcRn inhibition. Strong clinical outcomes, favorable safety profile, and updates to treatment guidelines have accelerated adoption across major markets.
• Based on route of administration, Intravenous (IV) Infusion dominated the route of administration segment in 2024, primarily due to its early commercial availability and widespread adoption in hospital settings for induction therapy. However, the market is witnessing a rapid shift towards subcutaneous formulations, particularly the recently approved prefilled syringe, which offers self-administration and greater patient convenience.
• North America led the Vyvgart market in 2024, supported by high diagnosis and treatment rates of autoimmune diseases, favorable reimbursement policies, and a robust specialty pharmacy infrastructure. The region also benefits from increasing clinical trial activity and early adoption of innovative immunotherapies.
• Argenx SE continued to lead the Vyvgart (Efgartigimod) market globally, leveraging its robust R&D pipeline, expanding international approvals, and strategic partnerships with regional players like Zai Lab in China. The company's focus on supply chain resilience, patient assistance programs, and platform-based development supports its long-term growth across multiple indications and geographies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Vyvgart (Efgartigimod) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
• 3.4. Pipeline Analysis
• 3.5. Patent Expiry Analysis
• 3.6. Pricing Analysis

Chapter 4. Vyvgart (Efgartigimod) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • 4.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, 2018 - 2030 (USD Million)
• 4.5. Generalized Myasthenia Gravis (gMG)
  • 4.5.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Vyvgart (Efgartigimod) Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2024 & 2030
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 5.4. Intravenous (IV) Infusion
  • 5.4.1. Intravenous (IV) Infusion Market, 2018 - 2030 (USD Million)
• 5.5. Subcutaneous (SC) Injection
  • 5.5.1. Subcutaneous (SC) Injection Market, 2018 - 2030 (USD Million)
• 5.6. Prefilled Syringes
  • 5.6.1. Prefilled Syringe Market, 2018 - 2030 (USD Million)

Chapter 6. Vyvgart (Efgartigimod) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Argenx SE
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives

Chapter 8. Conclusion